資源描述：
《立寶舒卡波姆眼用凝膠治療干眼的臨床觀察》由會員上傳分享，免費在線閱讀，更多相關(guān)內(nèi)容在工程資料-天天文庫。
1、立寶舒卡波姆眼用凝膠治療干眼的臨床觀察作者：鄧志宏，趙少貞，張未女札趙小云單位：中國天津市，天津醫(yī)科大學(xué)眼科中心【摘要】目的：通過觀察干眼癥患者使用2g/L立寶舒卡波姆眼用凝膠(簡稱立寶舒)前后，患者的主觀癥狀、視力、干眼實驗室檢查結(jié)果以及藥物的耐受性，評估立寶舒對干眼癥的療效。方法：選擇干眼癥患者100例200眼予以2g/L立寶舒卡波姆眼用凝膠滴雙眼，4次/d。觀察就診當(dāng)天、用藥7,14,28d后患者主觀癥狀：T燥感、異物感、酸痛感、眼疲勞、眼紅、畏光；視力、T眼實驗室檢查：淚膜破裂吋間(bre
2、akuptime,BUT).熒光素染色、SchinnerI試驗、SchinnerII試驗、臉板腺功能檢杳結(jié)果以及患者用藥的耐受性。結(jié)果：用藥7d后，患者的干燥感、異物感、酸痛感、眼疲勞、眼紅、畏光等主觀癥狀的分級與用藥前有顯著差異(P<0.01),隨著川藥時間的延長，6種主觀癥狀明顯緩解；但患者不同時間的視力無明顯差異(P>0.05)o用藥后患者的BUT及SchirmerI,SchirmerII值與用藥前有顯著差異(P<0.01),并H_隨著川藥時間的延長，患者BUT及Schin
3、YierI,SchirmerII值明顯延長；但不同時間的瞼板腺功能分級無明顯差異(P>；0.05)；川藥后患者熒光素染色分級及汨膜脂質(zhì)干涉Yakoi分級與用藥詢有顯著差異(P<0.01)o所有觀察病例中未發(fā)現(xiàn)明顯不耐受藥物的患者。結(jié)論：2g/L的立寶舒卡波姆眼用凝膠可以明顯改善干眼患者的眼部癥狀和干眼實驗室檢杏結(jié)果，藥物耐受性好，但對患者視力和瞼板腺功能無明顯改善作用?！娟P(guān)鍵詞】干眼立寶舒人工淚液ClinicalstudyofLiposicintreatingdryeyepatients
4、ZhiHongDeng,ShaoZhenZhao,WeiJuanZhang,XiaoYunZhaoEyeCenterofTianjinMedicalUniversity,Tianjin300070,ChinaAbstractAIM:ToinvestigatetheeffectofLiposicondryeye,wesurveythesubjectivesymptoms,visualacuity,andresultsoflaboratoryexaminationindryeyepatientsbef
5、oreandaftertreatedwithLiposic.METHODS:Onehundreddryeyepatients(200eyes)weretreatedLiposic,fourtimesaday.Thesubjectivesymptoms,laboratoryexaminationofdryeyeandtoleranceofpatientswereobservedonthevisitday,7,14,28daysaftertreatedwithLiposic.Thesubjective
6、symptomsincludedthedrysensation,foreignbodysensation,acliingpain,asthenopiaandphotophobia,andthelaboratoryexaminationofdryeyeincludedBUTtest,SchirmerItest(SIt),SchirmerIItest(SIIt),fluoresceinstaining,andexaminationinthefunctionofmeibomiangland.RESULT
7、S:AftertreatedwithLiposicfor7days,thesubjectivesymptomsofdryeyepatientswererelievedcomparedwithuntreatedpatients(P<0.01),butnosignificantdifferencecouldbeobservedinthevisualacuitybetweentreatedanduntreatedpatients(P>0.05).TheresultsofBUT,SItandS
8、IIt,fluoresceinstainingandYakoigradewerealsoimprovedaftertreatedwithLiposic(P<0.01).Butbutnosignificantdifferencecouldbeobservedinthefunctiontestofmeibomianglandbetweentreatedanduntreatedpatients(P>0.05).AllpatientsshowedgoodtolerancetoL
